Skip to main content

Table 2 Pulmonary function, exercise capacity and smoking history of subject groups

From: Inflammatory cytokine response to exercise in alpha-1-antitrypsin deficient COPD patients ‘on’ or ‘off’ augmentation therapy

  AATD + AUGa AATD-AUGb AATD PFTnormc non-AATD COPDd Healthye
FVC (liters) 3.85 ± 0.42 2.88 ± 0.16c 4.27 ± 0.64e 2.80 ± 0.32c,e 3.96 ± 0.57d
FVC (% pred) 88 ± 6c 79 ± 5c 109 ± 6e 77 ± 8c,e 95 ± 6d
FEV1 (liters) 1.23 ± 0.25c,e 1.35 ± 0.22c,e 3.22 ± 0.47e 1.49 ± 0.11c,e 3.07 ± 0.35d
FEV1 (% pred) 35 ± 5c,e 47 ± 7c,e 107 ± 4e 54 ± 7c,e 93 ± 4d
FEV1/FVC 31 ± 3c,d,e 47 ± 7c,e 76 ± 7c,e 56 ± 4c,e 79 ± 2d
FEV1/FVC (% pred) 40 ± 4c,d,e 61 ± 10c,e 97 ± 2e 71 ± 6c,e 99 ± 3d
Bike (two-legs) exercise      
Watts 62 ± 6c,e 46 ± 11c,e 176 ± 47d,e 70 ± 11c,e 126 ± 17d
VO2peak (L/min) 1.02 ± 0.11c,e 0.69 ± 0.13c,e 2.07 ± 0.51d 1.16 ± 0.12c,e 1.71 ± 0.25d
VO2peak (ml/kg/min) 12.6 ± 0.5c 9.5 ± 1.1c,e 26.9 ± 5.6d,e 14.9 ± 1.7c 20.3 ± 3.3
Knee extensor (single-leg) exercise      
Watts 25 ± 3c 21 ± 7c 59 ± 23d,e 21 ± 3c 26 ± 1
Smoking history      
Never 17% 0% 25% 0% 0%
Ex-smoker 83% 100% 75% 43% 100%
Current 0% 0% 0% 57% 0%
  1. Data are mean ± SE. AATD, alpha-1 antitrypsin deficient; AUG, augmentation therapy; PFTnorm, pulmonary function testing normal; AAT, alpha-1 antitrypsin; COPD, chronic obstructive pulmonary disease; FVC, forced vital capacity; FEV1, forced expiratory volume at 1 sec; VO2peak, peak oxygen consumption during exercise. Significance difference between group is denoted as follows, ‘c’ different compared to AATD PFTnorm,‘d’ different compared to COPD, ‘e’ different compared to Healthy. No differences with respect to AATD + AUG ‘a’ or AATD-AUG ‘b’ were found. In all cases, significance is p ≤ 0.05.